scholarly journals Recombinant factor VIIa to treat severe bleeding in patients with liver disease: Pitfalls and possibilities

2011 ◽  
Vol 55 (4) ◽  
pp. 950-951 ◽  
Author(s):  
Ton Lisman ◽  
Robert J. Porte
Keyword(s):  
Liver Disease ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Severe Bleeding

Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease

2005 ◽  
Vol 11 (8) ◽  
pp. 895-900 ◽  
Author(s):  
Raymond M. Planinsic ◽  
Jan van der Meer ◽  
Giuliano Testa ◽  
Luis Grande ◽  
Angel Candela ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Chronic Liver ◽  
Bolus Administration ◽  
Safety And Efficacy ◽  
Single Bolus

Recombinant Factor VIIa

2007 ◽  
Vol 18 (2) ◽  
pp. 141-148
Author(s):  
Louise Rose
Keyword(s):  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Case Reports ◽  
Controlled Trial ◽  
Red Blood Cell Transfusion ◽  
Severe Bleeding ◽  
Trauma Patients ◽  
Safety Issues ◽  
Uncontrolled Bleeding

Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest. rFVIIa was initially developed (and licensed) for the treatment of hemophilia. Increasingly, evidence suggests rFVIIa causes cessation of bleeding, improves coagulation markers, and reduces blood product use for treatment of severe bleeding due to other causes. The majority of evidence for nonlicensed use of rFVIIa consists of case reports. Recently, the first randomized controlled trial of rFVIIa in trauma patients reported a significant reduction in red blood cell transfusion, and a trend toward reduced mortality and critical complications. As evidence builds to support the use of rFVIIa, nurses need to be aware of the administration and safety issues of this treatment.

Use of Recombinant Factor VIIa to Correct the Coagulation Status of Individuals with Advanced Liver Disease Prior to a Percutaneous Liver Biopsy

2009 ◽  
Vol 54 (5) ◽  
pp. 1115-1119 ◽  
Author(s):  
Shabbar Sajjad ◽  
Moises Garcia ◽  
Ahmed Malik ◽  
Magdalena M. George ◽  
David H. Van Thiel
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Percutaneous Liver Biopsy ◽  
Advanced Liver Disease ◽  
Coagulation Status

scholarly journals Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease

2001 ◽  
Vol 66 (4) ◽  
pp. 292-294 ◽  
Author(s):  
Philip W. Friederich ◽  
Peter C. Wever ◽  
Ernest Briët ◽  
Cornelis J. Doorenbos ◽  
Marcel Levi
Keyword(s):  
Successful Treatment ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Von Willebrand Disease ◽  
Severe Bleeding ◽  
Acquired Von Willebrand Disease ◽  
Von Willebrand
Sign in / Sign up

Export Citation Format

Share Document